MARKET

ADAP

ADAP

Adaptimmune Therapeutics Plc
NASDAQ
0.2771
+0.0118
+4.45%
After Hours: 0.2800 +0.0029 +1.05% 19:28 04/28 EDT
OPEN
0.2700
PREV CLOSE
0.2653
HIGH
0.2875
LOW
0.2661
VOLUME
418.37K
TURNOVER
--
52 WEEK HIGH
1.480
52 WEEK LOW
0.1951
MARKET CAP
71.28M
P/E (TTM)
-0.9872
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADAP last week (0421-0425)?
Weekly Report · 20h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at ADAP last week (0414-0418)?
Weekly Report · 04/21 09:30
Adaptimmune Therapeutics CFO Departure Terms Revised
TipRanks · 04/14 20:28
ADAPTIMMUNE THERAPEUTICS PLC - CFO GAVIN WOOD'S TERMINATION DATE EXTENDED TO AUGUST 31, 2025 - SEC FILING
Reuters · 04/14 20:14
Weekly Report: what happened at ADAP last week (0407-0411)?
Weekly Report · 04/14 09:28
Adaptimmune downgraded to Hold from Buy at JonesResearch
TipRanks · 04/11 20:25
Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
TipRanks · 04/11 20:15
More
About ADAP
More
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Recently
Symbol
Price
%Change

Webull offers Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ: ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.